Dizal Pharmaceutical

The Next Frontier in Lung Cancer: Overcoming Treatment Resistance For patients battling non-small cell lung cancer (NSCLC), the journey often hits a devastating wall: drug resistance. While third-generation EGFR tyrosine kinase inhibitors (TKIs) have been a cornerstone of treatment, many patients inevitably see their cancer progress, often accompanied by the daunting challenge of brain metastases. … Read more

The Shift Toward Oral Targeted Therapies in Lung Cancer Treatment The landscape of oncology is undergoing a seismic shift. For decades, chemotherapy has been the standard-of-care for many lung cancer patients, often bringing with it a heavy toll on quality of life. However, the recent progress in treating non-small cell lung cancer (NSCLC) with EGFR … Read more